(RLAY) Relay Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.494m USD | Total Return: 375.6% in 12m
Avg Turnover: 40.8M
Qual. Beats: 0
Rev. Trend: 3.1%
Qual. Beats: 0
Warnings
Altman Z'' -15.00 < 1.0 - financial distress zone
Tailwinds
Leader, Tailwind
Relay Therapeutics, Inc. is a Cambridge-based clinical-stage biotechnology firm specializing in precision medicine for oncology and genetic diseases. The company utilizes a proprietary drug discovery platform focused on protein motion and computational modeling to develop small molecule therapeutics. Its clinical pipeline includes RLY-2608, targeting PI3Ka mutations in breast cancer, and lirafugratinib (RLY-4008), a selective FGFR2 inhibitor for solid tumors.
The company operates under a high-risk, research-intensive business model typical of the biotechnology sector, where value is primarily driven by clinical trial milestones and intellectual property. Unlike traditional drug discovery, Relay integrates structural biology and machine learning to identify allosteric binding sites that are often inaccessible via standard screening methods. Strategic collaborations with Pfizer and D. E. Shaw Research provide additional capital and technical resources for large-scale development programs.
Investors may find further insights into the companys valuation metrics by exploring ValueRay.
- RLY-2608 clinical data readouts determine progress in the breast cancer treatment market
- Pfizer partnership for combination therapies influences long-term revenue and development milestones
- Regulatory approval timelines for lirafugratinib impact the companys first commercial product launch
- High research and development expenditures necessitate future capital raises or strategic financing
- Clinical trial results for RLY-8161 drive investor confidence in the RAS protein pipeline
| Net Income: -272.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA 3.60 > 1.0 |
| NWC/Revenue: 5.89k% < 20% (prev 9.15k%; Δ -3.26k% < -1%) |
| CFO/TA -0.30 > 3% & CFO -213.4m > Net Income -272.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (179.8m) vs 12m ago 6.27% < -2% |
| Gross Margin: 73.28% > 18% (prev 0.47%; Δ 7.28k% > 0.5%) |
| Asset Turnover: 1.42% > 50% (prev 0.96%; Δ 0.46% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.90 (Total Current Assets 658.5m - Total Current Liabilities 29.8m) / Total Assets 699.6m |
| B: -2.98 (Retained Earnings -2.09b / Total Assets 699.6m) |
| C: -0.39 (EBIT TTM -290.7m / Avg Total Assets 749.5m) |
| D: -36.36 (Book Value of Equity -2.09b / Total Liabilities 57.4m) |
| Altman-Z'' = -44.62 = D |
As of May 24, 2026, the stock is trading at USD 13.66 with a total of 10,306,268 shares traded.
Over the past week, the price has changed by +10.90%,
over one month by -18.05%,
over three months by +51.34% and
over the past year by +375.57%.
Relay Therapeutics has received a consensus analysts rating of 4.31. Therefore, it is recommended to buy RLAY.
- StrongBuy: 6
- Buy: 5
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.8 | 67.1% |
P/B = 3.8873
Revenue TTM = 10.7m USD
EBIT TTM = -290.7m USD
EBITDA TTM = -287.9m USD
Long Term Debt = 27.7m USD (estimated: total debt 31.6m - short term 3.89m)
Short Term Debt = 3.89m USD (from shortTermDebt, last quarter)
Debt = 31.6m USD (from shortLongTermDebtTotal, last quarter) (leases 31.6m already included)
Net Debt = -610.5m USD (calculated: Debt 31.6m - CCE 642.1m)
Enterprise Value = 1.88b USD (2.49b + Debt 31.6m - CCE 642.1m)
Interest Coverage Ratio = unknown (Ebit TTM -290.7m / Interest Expense TTM 0.0)
EV/FCF = -8.83x (Enterprise Value 1.88b / FCF TTM -213.4m)
FCF Yield = -11.33% (FCF TTM -213.4m / Enterprise Value 1.88b)
FCF Margin = -2.00k% (FCF TTM -213.4m / Revenue TTM 10.7m)
Net Margin = -2.55k% (Net Income TTM -272.7m / Revenue TTM 10.7m)
Gross Margin = 73.28% ((Revenue TTM 10.7m - Cost of Revenue TTM 2.85m) / Revenue TTM)
Gross Margin QoQ = 83.20% (prev 91.44%)
Tobins Q-Ratio = 2.69 (Enterprise Value 1.88b / Total Assets 699.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 31.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -229.7m (EBIT -290.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.13 (Total Current Assets 658.5m / Total Current Liabilities 29.8m)
Debt / Equity = 0.05 (Debt 31.6m / totalStockholderEquity, last quarter 642.2m)
Debt / EBITDA = 2.12 (negative EBITDA) (Net Debt -610.5m / EBITDA -287.9m)
Debt / FCF = 2.86 (negative FCF - burning cash) (Net Debt -610.5m / FCF TTM -213.4m)
Total Stockholder Equity = 620.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.39% (Net Income -272.7m / Total Assets 699.6m)
RoE = -10.07% (Net Income TTM -272.7m / Total Stockholder Equity 2.71b)
RoCE = -10.62% (EBIT -290.7m / Capital Employed (Equity 2.71b + L.T.Debt 27.7m))
RoIC = -85.69% (negative operating profit) (NOPAT -229.7m / Invested Capital 268.0m)
WACC = 11.99% (E(2.49b)/V(2.53b) * Re(12.14%) + D(31.6m)/V(2.53b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 12.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 18.58%
[DCF] Fair Price = unknown (Cash Flow -213.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.25 | # QB: 0
Revenue Correlation: 3.14 | Revenue CAGR: 3.47% | SUE: -0.34 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.40 | Chg30d=-5.69% | Revisions=-33% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.41 | Chg30d=-7.05% | Revisions=-56% | Analysts=9
EPS current Year (2026-12-31): EPS=-1.63 | Chg30d=-6.65% | Revisions=-56% | GrowthEPS=-1.3% | GrowthRev=-40.4%
EPS next Year (2027-12-31): EPS=-1.72 | Chg30d=-11.55% | Revisions=-50% | GrowthEPS=-5.2% | GrowthRev=+114.3%
[Analyst] Revisions Ratio: -56%